FrancophonIA/ELRC3.0 huggingface dataset:
English: Other medicines that may lead to enhancement of the antihypertensive effect such as baclofen (a medicine for relief of spasticity), amifostin (used in cancer treatment) and some antipsychotic medicines.
Maltese: • Mediċini oħra li jistgħu jżidu l-effetti li jbaxxu l-pressjoni bħal baclofen (mediċina li tnaqqas li spasiċita), amifostin (tintuża għal kura tal-kanċer) u xi mediċini antipsikotiċi.
English: In patients with intravascular volume and/or sodium depletion symptomatic hypotension may occur, as described for other agents acting on the renin-angiotensin-aldosterone system.
Maltese: F' pazjenti bi tnaqqis fil-volum intravaskulari u/jew tnaqqis ta' sodium pressjoni baxxa tista' sseħħ, kif deskritta għal prodotti mediċinali li jaffettwaw is-sistema ta' renin-angiotensin-aldosterone.
English: OTHER Mon Tue Wed Thur Fri Sat Sun
Maltese: Jekk tuża Atacand Plus aktar milli suppost
English: As with ACE inhibitors, concomitant use of AIIRAs and NSAIDs may lead to an increased risk of worsening of renal function, including possible acute renal failure, and an increase in serum potassium, especially in patients with poor pre-existing renal function.
Maltese: Bħal ma jiġri b'impedituri ta' ACE, l-użu konkomitanti ta' AIIRAs u NSAIDs jista' jwassal għal żieda fir-riskju li l-funzjoni tal-kliewi tmur għall-agħar, inkluż il-possibbiltà ta' insuffiċjenza akuta talkliewi, u żieda fil-potassju fis-serum, speċjalment f'pazjenti li diġà jkollhom funzjoni tal-kliewi dgħajfa.
English: Dose titration of candesartan cilexetil is recommended when switching from hydrochlorothiazide monotherapy.
Maltese: Żieda fid-doża ta' candesartan cilexetil hija rakkomandata meta teqleb minn hydrochlorothiazide bħala monoterapija.
English: Concomitant treatment with baclofen, amifostin, tricyclic antidepressants or neuroleptics may lead to enhancement of the antihypertensive effect and may induce hypotension.
Maltese: Kura konkomittanti ma baclofen, amifostin, antidepressanti tricyclic jew newrolettiċi jistgħu jżidu leffett ta' kontra l-pressjoi għolja u jistgħu jinduuċu pressjoni baxxa.
English: Intravascular volume depletion
Maltese: Frekwenza Effetti Mhux Mixtieqa
English: Dose adjustment of antidiabetic medicinal products, including insulin, may be required.
Maltese: Aġġustar fid-doża ta' prodotti mediċinali antidijabetiċi, inkluż l-insulina, jista jkun meħtieġ.
English: Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.
Maltese: Metformin għandu jintuża b' kawtela minħabba r-riskju ta' aċidosi lattika indotta minn indeboliment funzjonali tal-kliewi relatata ma hydrochlorothiazide.
English: Following oral administration, candesartan cilexetil is converted to the active substance candesartan.
Maltese: Candesartan cilexetil huwa prodrug adattat għal użu orali.
English: Uncommon Postural hypotension Rare
Maltese: Rari ħafna Iperkalimja, iponatrimija
English: Cyclosporine, a medicine used for organ transplant to avoid organ rejection.
Maltese: • Cyclosporine, mediċina li tintuża għat-trapjant tal-organi sabiex tevita li l-organu jiżi riġettat.
English: Laxatives.
Maltese: • Lassattivi.
English: There were no qualitative new toxic findings with the combination compared to that observed for each component.
Maltese: Ma kien hemm l-ebda evidenza ta' tossiċità kwalitattiva ġdida bit-taħlita mqabbla ma dik osservata għall- kull komponent.
English: Concomitant intake of food increases the absorption by approximately 15%.
Maltese: Meta jingħata flimkien ma l-ikel, jiżdied l-assorbiment bejn wieħed u ieħor bi 15%.
English: No additional accumulation of hydrochlorothiazide occurs after repeated doses of the combination compared to monotherapy.
Maltese: Ma s-seħħ l-ebda akkumulazzjoni addizzjonali ta' hydrochlorothiazide wara dożi ripetuti tat-taħlita mqabbel ma monoterapija.
English: Dose titration of candesartan cilexetil is recommended in patients at risk for hypotension, such as patients with possible volume depletion (an initial dose of candesartan cilexetil of 4 mg may be considered in these patients).
Maltese: Żieda bil-mod fid-doża ta' candesartan cilexetil hija rakkomandata f' pazjenti li għandhom riskju ta' pressjoni baxxa, bħal pazjenti li jistgħu jkollhom tnaqqis fil-volum (doża inizjali ta' candesartan cilexetil ta' 4 mg tista' titqies f' dawn il- pazjenti).
English: Currently there are no data on the use of candesartan cilexetil/hydrochlorothiazide in patients with renal disease/nephropathy, reduced left ventricular function/congestive heart failure and post myocardial infarction.
Maltese: Bħalissa ma hemmx dejta dwar l-użu ta' candesartan cilexetil/hydrochlorothiazide f' pazjenti b' mard tal-kliewi/nefropatija, tnaqqis fil-funzjoni fil-ventrikolu tax-xellug/insufiċjenza konġestiva talqalb u wara infart mijokardijaku.
English: The expiry date refers to the last day of that month.
Maltese: It-Tieni u t-tielet trimestri ta' tqala.
English: Medicines for diabetes (tablets or insulin).
Maltese: • Mediċini għad-dijabete (pilloli jew insulina).
English: Anticholinergic agents such as atropine and biperiden.
Maltese: • Sustanzi antikolinerġiċi bħal atropina jew biperiden.
English: Periodic monitoring of serum potassium is recommended when Atacand Plus is administered with such medicinal products, and with the following medicinal products that could induce torsades de pointes:
Maltese: Monitoraġġ perjodiku tal-potassium fis-serum huwa rrakkomandat meta Atacand Plus jingħata ma dawn il-prodotti mediċinali u ma dawn il-prodotti mediċinali li ġejjin li jistgħu jinduċu torsades de pointes:
English: Worsening of existing lupus erythaematosus-like reactions or appearance of unusual skin reactions.
Maltese: • Aggravar ta' reazzjonijiet eżistenti bħal lupus erythaematosus jew apparenza ta' reazzjonijiet fil-ġilda mhux normali.
English: Because no information is available regarding the use of Atacand Plus during breastfeeding, Atacand Plus is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.
Maltese: Peress li m' hemmx informazzjoni disponibbli rigward l-użu ta' Atacand Plus waqt it-treddigħ, Atacand Plus mhux rakkomandat u kuri alternattivi li għandhom profil ta' sigurta aktar stabbilit u tajjeb waqt it-treddigħ huma preferuti speċjalment waqt treddigħ ta' tarbija tat-twelid jew tarbija li titwieled qabel iż-żmien.
English: Itching.
Maltese: Treddigħ
English: There is no clinically significant interaction between hydrochlorothiazide and food.
Maltese: Ma hemmx interazzjoni klinikament sinifikanti bejn hydrochlorothiazide u l-ikel.
English: Medicines that can be affected by potassium blood levels such as some antipsychotic medicines.
Maltese: • Mediċini li jistgħu jkunu affetwati bil-livelli ta' potassium fid-demm bħal xi mediċini antipsikotiċi.
English: Use of candesartan and hydrochlorothiazide with lithium is not recommended.
Maltese: L-użu ta' candesartan u hydrochlorothiazide ma lithium mhux rakkomandat.
English: Cough
Maltese: Komini
English: Latent diabetes mellitus may become manifest during thiazide therapy.
Maltese: Diabetes mellitus li għadha ma bdietx tidher tista toħroġ waqt kura b' thiazide.
English: The name of your medicine is Atacand Plus.
Maltese: Huwa mportanti li tibqa tieħu Atacand Plus kuljum.
English: Hydrochlorothiazide may cause the arterial response to pressor amines (e.g. adrenaline) to decrease but not enough to exclude a pressor effect.
Maltese: Hydrochlorothiazide jista jikkawża r-rispons arterjali għall-pressuri amines (eż adrenaline) sabiex inaqqas iżda mhux biżżejjed sabiex jeskludi effett pressur.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING AND THE IMMEDIATE PACKAGING CARTON FOR BLISTER / CARTON FOR BOTTLE / LABEL FOR BOTTLE
Maltese: KARTUNA GĦALL-FOLJA/KARTUNA GĦALL-FLIXKUN/TIKKETTA GĦALL-FLIXKUN
English: Patients with primary hyperaldosteronism generally will not respond to antihypertensive agents acting through inhibition of the renin-angiotensin-aldosterone system.
Maltese: Pazjenti b'iperaldosteroniżmu primarju ġeneralment ma jirrispondux għal prodotti mediċinali kontra l-pressjoni għolja li jaħdmu permezz ta' impediment fuq is-sistema tar-renin-angiotensinaldosterone.
English: you have a disease of the adrenal gland called Conn's syndrome (also called primary hyperaldosteronism).
Maltese: • Jekk għandek mard tal-glandola adrenali tissejjaħ sindrome Cronn's (tissejjaħ ukoll iperaldosteronismu primarja)
English: Opening date:_________
Maltese: Data tal-ftuħ: :_________
English: Accord Healthcare Polska Sp. z o.o.
Maltese: Accord Healthcare Polska Sp. z o.o. ul.
English: World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Spain
Maltese: World Trade Center, Moll de Barcelona s/n, Edifici Est, 6a planta, Barcelona, 08039 Barcelona, Spanja
English: H-1045 Budapest HUNGARY
Maltese: H-1045 Budapest L-UNGERIJA
English: MARKETING AUTHORISATION NUMBER(S) EU/1/19/1380/001
Maltese: EU/1/19/1380/001
English: EUCAST ECOFF values: - Aspergillus flavus: 0.5 mg/L - Aspergillus fumigatus: 0.25 mg/L - Aspergillus nidulans: 0.5 mg/L - Aspergillus niger: 0.5 mg/L - Aspergillus terreus: 0.25 mg/L
Maltese: - Aspergillus flavus: 0.5 mg/L - Aspergillus fumigatus: 0.25 mg/L - Aspergillus nidulans: 0.5 mg/L - Aspergillus niger: 0.5 mg/L - Aspergillus terreus: 0.25 mg/L
English: Simeticone emulsion (containing polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) and sulfuric acid (E513))
Maltese: Emulsjoni ta' simethicone (li fiha polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) u sulfuric acid (E513))
English: EUCAST MIC breakpoints for posaconazole [susceptible (S); resistant (R)]:
Maltese: MIC ta' EUCAST għal posaconazole [suxxettibbli (S); reżistenti (R)]:
English: 105 mL
Maltese: Suspensjoni orali 105 mL
English: Posaconazole has been shown in vitro to be active against the following microorganisms: Aspergillus species (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), Candida species (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, and species of Fusarium, Rhizomucor, Mucor, and Rhizopus.
Maltese: Speċi ta' Aspergillus (Aspergillus fumigatus, A. flavus, A. terreus, A. nidulans, A. niger, A. ustus), speċi ta' Candida (Candida albicans, C. glabrata, C. krusei, C. parapsilosis, C. tropicalis, C. dubliniensis, C. famata, C. inconspicua, C. lipolytica, C. norvegensis, C. pseudotropicalis), Coccidioides immitis, Fonsecaea pedrosoi, u speċi ta' Fusarium, Rhizomucor, Mucor, u Rhizopus.
English: Posaconazole inhibits the enzyme lanosterol 14α-demethylase (CYP51), which catalyses an essential step in ergosterol biosynthesis.
Maltese: Posoconazole jinibixxi l-enzima lanosterol 14α-demethylase (CYP51), li tikkatalizza pass essenzjali fil-biosintesi ta' ergosterol.
English: nd day, then 400 mg twice daily x 8 Days) by 21 % and 23 %, respectively.
Maltese: 8 ijiem) b'21 % u 23 %, rispettivament.
English: New diagnosis of acute myelogenous leukaemia was the most common underlying condition (435/602, [72 %]).
Maltese: Lewkimja majeloġenuża li tkun għadha kif ġiet dijanjostikata hija l-aktar kundizzjoni komuni (435/602, [72%]).
English: The other ingredients in the suspension are macrogolglycerol hydroxystearate, sodium citrate dihydrate, citric acid monohydrate, simeticone emulsion (containing polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) and sulfuric acid (E513)), xanthan gum (E415), sodium benzoate (E211), liquid glucose, glycerol (E422), titanium dioxide (E171), strawberry flavour (containing propylene glycol) and purified water.
Maltese: Is-sustanzi l-oħra mhux attivi huma simeticonemacrogolglycerol hydroxystearate, sodium benzoate (E211), sodium citrate dihydrate, citric acid monohydrate, glycerol, xanthan gum, simeticone emulsion (containing polydimethylsiloxane, polyethylene glycol sorbitan tristearate, methylcellulose, silica gel, polyethylene glycol stearate, sorbic acid (E200), benzoic acid (E210) and sulfuric acid (E513)), xanthan gum (E415), sodium benzoate (E211), glucose likwidu, glycerol (E422), titanium dioxide (E171), togħma artifiċjali tal-frawli (li fiha propylene glycol) u ilma purifikat.
English: Tabulated list of adverse reactions Within the organ system classes, adverse reactions are listed under headings of frequency using the following categories: very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥ 1/10,000 to <1/1,000); very rare (<1/10,000); not known.
Maltese: Lista tar-reazzjonijiet avversi miġbura f'tabella Fost is-sistema tal-klassifika tal-organi, l-effetti avversi huma mniżżla skont il-frekwenza permezz tal-kategoriji li ġejjin: komuni ħafna (≥1/10); komuni (≥1/100 sa <1/10); mhux komuni (≥1/1,000 sa <1/100); rari (≥ 1/10,000 sa <1/1,000); rari ħafna (<1/10,000); mhux magħruf.
English: The principle mechanism of resistance is the acquisition of substitutions in the target protein, CYP51.
Maltese: Il-mekkaniżmu prinċipali ta' reżitsenza huwa l'akkwist ta' sostituzzjonijiet fil-proteina li tkun immirata, CYP51.
English: The mean duration of therapy was 80 days for posaconazole and 77 days for fluconazole.
Maltese: Bħala medja t-terapija damet 80 jum għal posaconazole u 77 jum għal fluconazole.
English: Gastrointestinal dysfunction
Maltese: Disturbi gastro-intestinali
English: A key secondary endpoint was the incidence of proven/probable IFIs at 100 days post-randomization.
Maltese: Endpoint sekondarju essenzjali kien l-inċidenza ta' IFI's li probabbli/ġew pruvati wara 100 jum minn meta saret ir-randomisation.
English: Controla Proportion (%) of patients with proven/probable Aspergillosis On-treatment periodb
Maltese: Proporzjon (%) ta' pazjenti b'Asperġillożi ppruvata/probabbli Perijodu fuq il-kurab
English: Midazolam and other benzodiazepines metabolised by CYP3A4
Maltese: Midazolam u benzodijażepini oħrajn metabolizzati b'CYP3A4
English: In subjects with severe renal impairment (n=6, Cl cr< 20 mL/min/1.73 m2), the AUC of posaconazole was highly variable [> 96 % CV (coefficient of variance)] compared to other renal groups [< 40 % CV].
Maltese: F'individwi li jkollhom insuffiċjenza renali severa (n=6, Cl cr < 20 mL/min/1.73 m2), l-AUC ta' posaconazole varja ħafna [> 96 % CV (koeffiċjenti tal-varjanza)] imqabbel mal-gruppi renali l-oħrajn [< 40 % CV].
English: Vincristine toxicity
Maltese: Tossiċità b'vincristine
English: Posaconazole AHCL 40 mg/mL oral suspension posaconazole
Maltese: Posaconazole AHCL 40 mg/mL suspensjoni orali posaconazole
English: Elderly (≥ 65 years) An increase in Cmax (26 %) and AUC (29 %) was observed in elderly subjects (24 subjects ≥ 65 years of age) relative to younger subjects (24 subjects 18 - 45 years of age).
Maltese: Żieda fis-Cmax (26 %) u l-AUC (29 %) dehret f'individwi anzjani (24 individwu ≥ 65 sena) relattiv ma' individwi aktar żgħar (24 individwu ta' bejn 18 - 45 sena).
English: Pharmacokinetic / Pharmacodynamic relationships A correlation between total medicinal product exposure divided by MIC (AUC/MIC) and clinical outcome was observed.
Maltese: Korrelazzjoni bejn l-esponiment totali tal-prodott mediċinali diviż bl-MIC (AUC/MIC) u r-riżultat kliniku kienet osservata.
English: Proportion (%) of patients with proven/probable IFIs On-treatment periodb
Maltese: Proporzjon (%) ta' pazjenti b'IFIs pruvati/probabbli Perjodu fuq il-kurab
English: Rifabutin (300 mg once a day) decreased the Cmax (maximum plasma concentration) and AUC (area under the plasma concentration time curve) of posaconazole to 57 % and 51 %, respectively.
Maltese: Rifabutin (300 mg darba kuljum) inaqqas is-Cmax (l-ogħla konċentrazzjoni fil-plażma) u l-AUC (erja taħt il-kurva tal-konċentrazzjoni fil-plażma mal-ħin) ta' posaconzole għal 57 % u 51 %
English: The safety of posaconazole tablet has been assessed in 336 patients and healthy volunteers enrolled in clinical trials.
Maltese: Is-sigurtà ta' posaconazole pillola ġiet ivvalutat fi 336 pazent u voluntiera b'saħħithom irreġistrati fil- provi kliniċi.
English: Posaconazole is also available as 100 mg gastro-resistant tablet and 300 mg concentrate for solution for infusion.
Maltese: Posaconazole huwa disponibbli wkoll bħala 100 mg pilloli gastro-reżistenti u 300 mg ta' konċentrat għal soluzzjoni għall-infużjoni.
English: Pharmacotherapeutic group: Antimycotics for systemic use, triazole derivatives, ATC code: J02AC04.
Maltese: Mediċini kontra l-fungu għall-użu sistemiku, derivati triazole, Kodiċi ATC:
English: Based on Kaplan-Meier estimates, the probability of survival up to day 100 after randomization, was significantly higher for posaconazole recipients; this survival benefit was demonstrated when the analysis considered all causes of death (P= 0.0354) as well as IFI-related deaths (P = 0.0209).
Maltese: Minn stimi Kaplan-Meier, ilprobabilità ta' sopravivenza sa' jum 100 wara li kienu randomized, kienet ogħla b'mod sinifikanti għar-riċevituri ta' posaconazole; dan il-benefiċċju ta' sopravivenza intwera meta l-analiżi qieset il-kawżi kollha ta' mwiet (P= 0.0354) kif ukoll imwiet relatati ma' IFI's (P= 0.0209).
English: Prophylaxis of Invasive Fungal Infections (IFIs) (Studies 316 and 1899) Two randomised, controlled prophylaxis studies were conducted among patients at high risk for developing invasive fungal infections.
Maltese: Profilassi ta' Infezzjonijiet Invażivi tal-Fungu (IFIs) (Studji 316 u 1899) Żewġ studji ta' profilassi randomised bil-kontroll saru b'pazjenti li għandhom riskju ogħla li jiżviluppaw infezzjonijiet invażivi tal-fungu.
English: - Candida albicans: S ≤0.06 mg/L, R >0.06 mg/L - Candida tropicalis: S ≤0.06 mg/L, R >0.06 mg/L - Candida parapsilosis: S ≤0.06 mg/L, R >0.06 mg/L
Maltese: S ≤0.06 mg/L, R >0.06 mg/L - Candida parapsilosis:
English: ECOFF values do not equate to clinical breakpoints.
Maltese: Il- valuri ECOFF mhumiex daqs il-breakpoints kliniċi.
English: Following administration of 800 mg per day of posaconazole as a divided dose for treatment of invasive fungal infections, mean trough plasma concentrations from 12 patients 8 - 17 years of age (776 ng/mL) were similar to concentrations from 194 patients 18 - 64 years of age (817 ng/mL).
Maltese: Wara li jingħataw 800 mg posaconazole kuljum bħala dożi maqsuma għall-kura ta' infezzjonijiet invażivi tal-fungu, il-medja tal-konċentrazzjonijiet fil-plażma minn 12-il pazjent ta' etajiet bejn 8 - 17- il sena (776 ng/mL) kienu simili għall-konċentrazzjonijiet minn 194 pazjent ta' etajiet bejn 18 - 64- il sena (817 ng/mL).
English: Study 316 was a randomised, double-blind trial of posaconazole oral suspension (200 mg three times a day) versus fluconazole capsules (400 mg once daily) in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease (GVHD).
Maltese: Studju 316 kien prova randomised, double-blind b'suspensjoni orali ta' posaconazole (200 mg tliet darbiet kuljum) kontra kapsuli ta' fluconazole (400 mg darba kuljum) f'riċevituri ta'
English: Effects of other medicinal products on posaconazole Posaconazole is metabolised via UDP glucuronidation (phase 2 enzymes) and is a substrate for p-glycoprotein (P-gp) efflux in vitro.
Maltese: Interazzjoni ma' prodotti mediċinali oħra u forom oħra ta' interazzjoni Effetti ta' prodotti mediċinali oħrajn fuq posaconazole Posaconazole jiġi metabolizzat permezz ta' glukoronidazzjoni UDP (enzimi ta' fażi 2) u huwa sottostrat għall-effluss ta' glikoproteina-p (P-gp) in vitro.
English: NAME OF THE MEDICINAL PRODUCT Posaconazole AHCL 40 mg/mL oral suspension
Maltese: Posaconazole AHCL 40 mg/mL suspensjoni orali
English: After a single oral dose of 400 mg posaconazole oral suspension to patients with mild (Child-Pugh Class A), moderate (Child-Pugh Class B) or severe (Child-Pugh Class C) hepatic impairment (six per group), the mean AUC was 1.3 to 1.6-fold higher compared to that for matched control subjects with normal hepatic function.
Maltese: Wara doża waħda ta' 400 mg posaconazole suspensjoni orali mill-ħalq lil pazjenti b'indeoliment epatiku ħafif (Klassi Child-Pugh A), moderat (Klassi Child-Pugh B), jew sever (Klassi Child-Pugh C) (sitta f'kull grupp), il-medju tal-AUC kien 1.3 sa' 1.6-il darba ogħla meta mqabbel ma' dak ta' individwi immeċċjati bħala kontroll b'funzjoni epatika normali.
English: The majority (377/600, [63 %]) of patients included had Acute Grade 2 or 3 or chronic extensive (195/600, [32.5%]) GVHD at study start.
Maltese: GVHD Akut ta' Grad 2 jew 3 jew kroniku estensiv (195/600, [32.5%]) mal-bidu tal-istudju.
English: See “Other medicines and Posaconazole AHCL” below for more information including information on other medicines which may interact with Posaconazole AHCL.
Maltese: Ara “Mediċini oħra u Posaconazole AHCL” hawn isfel għal aktar informazzjoni, inkluża informazzjoni dwar mediċini oħra li jistgħu jinteraġixxu ma' Posaconazole AHCL.
English: Phenytoin (200 mg once a day) decreased the Cmax and AUC of posaconazole by 41 % and 50 %, respectively.
Maltese: Phenytoin Phenytoin (200 mg darba kuljum) jnaqqas is-Cmax u l-AUC ta' posaconazole b'41 % u 50 %
English: FLU = fluconazole; ITZ = itraconazole; POS = posaconazole.
Maltese: M'hemmx tagħrif dwar l-effett tal-alkoħol fuq posaconazole.
English: Posaconazole may substantially increase plasma levels of HMG-CoA reductase inhibitors that are metabolised by CYP3A4.
Maltese: Posaconazole jista' jżid b'mod sostanzjali l-livelli fil-plażma ta' impedituri ta' HMG-CoA reductase li huma metabolizzati minn CYP3A4.
English: The primary efficacy endpoint was the incidence of proven/probable IFIs as determined by an independent, blinded external expert panel during the on-treatment period.
Maltese: L-endpoint tal- effikaċja ewlieni kien l-inċidenza ta' IFI's li probabbli/ġew pruvati li seħħew minn pannell estern ta' esperti indipendenti blinded waqt il-perijodu tal-kura.
English: Posaconazole had no effect on fertility of male rats at doses up to 180 mg/kg (1.7 times the 400 mg twice daily regimen based on steady-state plasma concentrations in healthy volunteers) or female rats at a dose up to 45 mg/kg (2.2 times the 400-mg twice daily regimen).
Maltese: Posaconazole ma kellux effett fuq il-fertilità ta' firien maskili b'dożi sa' 180 mg/kg (1.7-il darba tal- kors ta' 400 mg darbtejn kuljum ibbażat fuq il-konċentrazzjonijiet fil-plażma fi stat fiss f'voluntiera b'saħħithom) jew firien femminili b'doża sa 45 mg/kg (2.2-il darba tal-kors ta' 400 mgdarbtejn kuljum).
English: H2 receptor antagonists and proton pump inhibitors Posaconazole plasma concentrations (Cmax and AUC) were reduced by 39 % when posaconazole was administered with cimetidine (400 mg twice a day) due to reduced absorption possibly secondary to a decrease in gastric acid production.
Maltese: Antagonisti tar-riċettur H2 u impedituri tal-pompa tal-protoni Il-konċentrazzjonijiet fil-plażma ta' posaconazole (Cmax u AUC) kienu mnaqqsa b'39% meta posaconazole ingħata ma' cimetidine (400 mg darbtejn kuljum) minħabba tnaqqis fl-assorbiment li jista' jkun effett sekondarju għal tnaqqis tal-aċidu gastriku.
English: Posaconazole AHCL contains a medicine called posaconazole.
Maltese: Posaconazole AHCL fih mediċina msejħa posaconazole.
English: torsade de pointes, sudden death, ventricular tachycardia, cardio-respiratory arrest, cardiac failure, myocardial infarction
Maltese: arrest kardjo-respiratorju, insuffiċjenza kardijaka, infart majokardijaku
English: The elimination half-life (t1/2) was prolonged from approximately 27 hours up to ~43 hours in respective groups.
Maltese: Il-half-life tal-eliminazzjoni (t½) kien imtawwal minn madwar 27 siegħa sa ~43 siegħa fil-gruppi rispettivi.